guanfacine has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Guanfacine is a α2A adrenergic receptor agonist approved for treating attention deficit hyperactivity disorder (ADHD)." | 3.11 | Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments. ( Fox, C; Golemme, M; Hoang, K; Howard, R; Malhotra, PA; Perry, RJ; Pickett, J; Ritchie, C; Watt, H; Wilson, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoang, K | 1 |
| Watt, H | 1 |
| Golemme, M | 1 |
| Perry, RJ | 1 |
| Ritchie, C | 1 |
| Wilson, D | 1 |
| Pickett, J | 1 |
| Fox, C | 1 |
| Howard, R | 1 |
| Malhotra, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease[NCT03116126] | Phase 3 | 160 participants (Anticipated) | Interventional | 2019-01-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for guanfacine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.
Topics: Activities of Daily Living; Alzheimer Disease; Attention Deficit Disorder with Hyperactivity; Cholin | 2022 |